These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9890518)

  • 1. Evaluation of potency for well characterized biotechnology proteins.
    Finbloom DS
    Dev Biol Stand; 1998; 96():63-4. PubMed ID: 9890518
    [No Abstract]   [Full Text] [Related]  

  • 2. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 3. The quality control of biotechnology products.
    Federici MM
    Biologicals; 1994 Jun; 22(2):151-9. PubMed ID: 7917231
    [No Abstract]   [Full Text] [Related]  

  • 4. Purity of biological products: related and unrelated impurities.
    Herman AC
    Dev Biol Stand; 1998; 96():57-62. PubMed ID: 9890517
    [No Abstract]   [Full Text] [Related]  

  • 5. Endotoxin removal and prevention for pre-clinical biologics production.
    Serdakowski London A; Kerins B; Tschantz WR; Eisfeld J; Mackay K
    Biotechnol J; 2012 Dec; 7(12):1509-16. PubMed ID: 23081824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of product comparability.
    Builder SE
    Dev Biol Stand; 1998; 96():83-90. PubMed ID: 9890520
    [No Abstract]   [Full Text] [Related]  

  • 8. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of criteria for determining comparability of "well-characterized" proteins.
    Cavagnaro JA
    Dev Biol Stand; 1998; 96():79-81. PubMed ID: 9890519
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of assay validation in specification development.
    Baffi RA
    Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological assays: their role in the development and quality control of recombinant biological medicinal products.
    Mire-Sluis AR; Gerrard T; Das RG; Padilla A; Thorpe R
    Biologicals; 1996 Dec; 24(4):351-62. PubMed ID: 9088552
    [No Abstract]   [Full Text] [Related]  

  • 13. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of bioassays in the assessment of recombinant proteins.
    Jeffcoate SL
    Dev Biol Stand; 1994; 83():159-64. PubMed ID: 7883090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICH activities on biotech topics.
    Zorzi-Morre P
    Dev Biol Stand; 1999; 100():151-3. PubMed ID: 10616186
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic stability: an issue of product quality.
    Burns N
    Biologicals; 1993 Jun; 21(2):145-6. PubMed ID: 8297594
    [No Abstract]   [Full Text] [Related]  

  • 17. Bioassays and biological stability.
    Wright JF
    Dev Biol Stand; 1999; 97():73-80. PubMed ID: 10463532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology.
    Thorpe R; Wadhwa M; Mire-Sluis A
    Dev Biol Stand; 1997; 91():79-88. PubMed ID: 9413686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships among product characterization, process validation and preclinical/clinical studies for well-characterized products.
    Lubiniecki AS
    Dev Biol Stand; 1998; 96():173-5; discussion 177-9. PubMed ID: 9890530
    [No Abstract]   [Full Text] [Related]  

  • 20. Mass spectrometry in the standardisation of recombinant products.
    Geisow MJ
    Dev Biol Stand; 1994; 83():129-33. PubMed ID: 7883085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.